© Synapse Social LLC, 2026
June 4, 2026
Re: ‘Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma’ MM Maajid Mohi Ud Din Malik Dr. D.Y. Patil Vidyapeeth, Pune
Key Points This analysis aims to assess the cost-effectiveness of lisocabtagene maraleucel as a second-line treatment for relapsed large B-cell lymphoma. Evaluated the healthcare costs associated with lisocabtagene maraleucel treatment. Analyzed potential outcomes against existing second-line therapies. Findings indicate significant cost variations when comparing treatments. Limitations include the absence of primary data due to no datasets generated. Abstract Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Maajid Mohi Ud Din Malik (Mon,) studied this question.
Re: ‘Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma’ | Synapse
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study 2016 · 134 citations